MedTrace Logo

Registry Experience at the Washington Hospital Center With Drug Eluting Stents - Synergy

NCT02823730 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-05-26

No results posted yet for this study

Summary

To compare the incidence of major adverse cardiac events among a series of patients receiving the Synergy drug-eluting stent with bioabsorbable polymer to historical controls who have received the Promus Premier drug-eluting stent with durable polymer.

Conditions

  • Incidence of Major Adverse Cardiac Events

Interventions

OTHER

PCI with Synergy Stent

500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).

Sponsors & Collaborators

  • Medstar Health Research Institute

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02823730 on ClinicalTrials.gov